Glenmark Pharmaceuticals Launches Calcium Gluconate Injection in the U.S.; Targets $69.9 Million Market

BY ADMIN • FILED 21 Aug 2026, 12:27 PM

Mumbai, August 21, 2026: Glenmark Pharmaceuticals Limited has announced that its U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Calcium Gluconate Injection USP in multiple strengths and packaging formats in the U.S. market. The launch strengthens the company’s hospital-focused injectables portfolio and supports its strategy of expanding its presence in the U.S. healthcare market.

Glenmark Launches Calcium Gluconate Injection in the U.S.

Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. The product is bioequivalent and therapeutically equivalent to the reference listed drug Calcium Gluconate Injection of Fresenius Kabi USA, LLC, under NDA 208418.

$69.9 Million Market Opportunity

According to IQVIA sales data for the 12-month period ending June 2026, the U.S. market for the Calcium Gluconate Injection strengths covered by the launch recorded annual sales of approximately $69.9 million. The market figure includes the brand and available therapeutic equivalents. Glenmark has clarified that its product will be marketed only for the indications included in its approved label.

Strengthening U.S. Injectables Business

The launch is part of Glenmark’s strategy to strengthen its U.S. injectables business and expand its hospital portfolio. The company said the move is aimed at building a differentiated and sustainable injectables business that addresses institutional healthcare requirements, supports supply resilience and increases Glenmark’s presence across the U.S. healthcare system.

Management Commentary

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals, said the Calcium Gluconate Injection launch represents another important step in strengthening the company’s U.S. injectables business and expanding its hospital portfolio. He highlighted the company’s focus on disciplined execution, institutional needs, supply resilience and building a stronger position within the U.S. healthcare system.

Why the Launch Matters for Glenmark

The U.S. pharmaceutical market remains an important growth opportunity for Glenmark, and injectable products can help the company diversify its portfolio beyond traditional formulations. The Calcium Gluconate Injection launch provides Glenmark with access to a market that recorded approximately $69.9 million in annual sales for the relevant products and therapeutic equivalents, based on IQVIA data.

The launch also aligns with Glenmark’s broader focus on building its portfolio across branded, innovative, generic and consumer healthcare products, with key therapeutic areas including respiratory, dermatology and oncology.

Glenmark Pharmaceuticals: Global Presence

Glenmark Pharmaceuticals is a global, research-led pharmaceutical company focused on innovation and accessibility. The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and has a commercial presence in more than 80 countries. Its portfolio spans branded, innovative, generic and consumer healthcare products.

Key Takeaways for Investors

Glenmark Pharmaceuticals has launched Calcium Gluconate Injection USP in the U.S.
The product is available in 1,000 mg/10 mL, 5,000 mg/50 mL and 10,000 mg/100 mL formats.
The launch includes single-dose vials and a pharmacy bulk package.
The product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA.
The relevant U.S. market recorded approximately $69.9 million in annual sales for the 12 months ended June 2026, according to IQVIA data cited by Glenmark.
The launch strengthens Glenmark’s U.S. hospital and injectables portfolio.
The company sees the move as part of its strategy to build a differentiated and sustainable U.S. injectables business.

Stock Market Impact

The announcement is positive from a business-development perspective, as the launch expands Glenmark’s U.S. injectable portfolio and gives the company exposure to a market with reported annual sales of approximately $69.9 million for the relevant product category. However, the actual financial contribution to Glenmark will depend on market share, pricing, competition, volumes and the timing of the product ramp-up. Investors should therefore distinguish between the reported market size and Glenmark’s potential revenue opportunity.

Disclaimer: This article is based on information disclosed by Glenmark Pharmaceuticals Limited in its exchange filing and accompanying media release. The market-size figure and product information have been reproduced from the company’s disclosure. This article is for informational and educational purposes only and should not be considered investment advice. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.